CBL - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	CXCR5	C-X-C motif chemokine receptor 5	Chemokine receptors bind chemokines G alpha (i) signalling events
Novel	ETS1	ETS proto-oncogene 1, transcription factor	Oncogene Induced Senescence
	ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	Regulation of actin dynamics for phagocytic cup formation Role of ABL in ROBO-SLIT signaling Role of ABL in ROBO-SLIT signaling Myogenesis Myogenesis RHO GTPases Activate WASPs and WAVEs HDR through Single Strand Annealing (SSA) Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Cyclin D associated events in G1 RUNX1 regulates transcription of genes involved in differentiation of HSCs RUNX2 regulates osteoblast differentiation FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production	ATP Imatinib Dasatinib N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide Nilotinib XL228 Bosutinib 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA Myristic acid PD-166326 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide Regorafenib Ponatinib Fostamatinib Brigatinib Radotinib	Chronic myeloid leukemia (CML) Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
	APPL1	adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1	Caspase activation via Dependence Receptors in the absence of ligand
	ASAP1	ArfGAP with SH3 domain, ankyrin repeat and PH domain 1	VxPx cargo-targeting to cilium VxPx cargo-targeting to cilium
	AXL	AXL receptor tyrosine kinase	VEGFA-VEGFR2 Pathway	Fostamatinib Gilteritinib
	BCR	BCR activator of RhoGEF and GTPase	Signaling by cytosolic FGFR1 fusion mutants Rho GTPase cycle Signaling by FGFR1 in disease	Imatinib Dasatinib Bosutinib Ponatinib	Chronic myeloid leukemia (CML) Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
	BLK	BLK proto-oncogene, Src family tyrosine kinase	RUNX1 regulates transcription of genes involved in BCR signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Fostamatinib Zanubrutinib	Maturity onset diabetes of the young (MODY)
	BLNK	B cell linker	Regulation of signaling by CBL Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers		Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
	BTK	Bruton tyrosine kinase	ER-Phagosome pathway MyD88:MAL(TIRAP) cascade initiated on plasma membrane Regulation of actin dynamics for phagocytic cup formation DAP12 signaling FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization G alpha (q) signalling events G alpha (12/13) signalling events MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) RHO GTPases Activate WASPs and WAVEs G beta:gamma signalling through BTK FCGR3A-mediated phagocytosis Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Dasatinib Inositol 1,3,4,5-Tetrakisphosphate XL418 Ibrutinib Acalabrutinib Fostamatinib Zanubrutinib Abivertinib	Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8 Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
	CAPN1	calpain 1	Degradation of the extracellular matrix Degradation of the extracellular matrix Neutrophil degranulation Formation of the cornified envelope Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	4-[[(2S)-2-[[(2S)-3-Carboxy-2-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]butyl-(diaminomethylidene)azanium N-[(benzyloxy)carbonyl]-L-leucyl-N-[(1S)-3-fluoro-1-(4-hydroxybenzyl)-2-oxopropyl]-L-leucinamide (2S)-4-METHYL-2-(3-PHENYLTHIOUREIDO)-N-((3S)-TETRAHYDRO-2-HYDROXY-3-FURANYL)PENTANAMIDE
	CBLIF	cobalamin binding intrinsic factor	Cobalamin (Cbl, vitamin B12) transport and metabolism Defective GIF causes intrinsic factor deficiency Defective AMN causes hereditary megaloblastic anemia 1 Defective CUBN causes hereditary megaloblastic anemia 1
	CD19	CD19 molecule	PIP3 activates AKT signaling Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of Complement cascade Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Coltuximab ravtansine Blinatumomab Inebilizumab Tisagenlecleucel Axicabtagene ciloleucel Tafasitamab Brexucabtagene autoleucel	Common variable immunodeficiency (CVID), including the following four diseases: Inducible T Cell costimulator (ICOS) defect; TACI defect; CD19 defect; BAFFR defect
	CD2AP	CD2 associated protein	Nephrin family interactions		Nephrotic syndrome and focal segmental glomerulosclerosis
	CD38	CD38 molecule	Nicotinate metabolism	Daratumumab Isatuximab Mezagitamab
	CD40	CD40 molecule		Lucatumumab Dacetuzumab	Hyper IgM syndromes, autosomal recessive type, including the following three diseases: Activation-induced cytidine deaminase (AICD) defect; Uracil nucleotide glycoside glycosylase (UNG) defect; Immunodeficiency with hyper-IgM type 3 Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
	CD5	CD5 molecule
	CDKL2	cyclin dependent kinase like 2		Fostamatinib
	CRK	CRK proto-oncogene, adaptor protein	ARMS-mediated activation ARMS-mediated activation Downstream signal transduction Regulation of actin dynamics for phagocytic cup formation p130Cas linkage to MAPK signaling for integrins VEGFA-VEGFR2 Pathway PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAP1 and RAC1 MET receptor recycling Regulation of signaling by CBL FCGR3A-mediated phagocytosis
	CRKL	CRK like proto-oncogene, adaptor protein	Frs2-mediated activation Frs2-mediated activation Downstream signal transduction MET activates RAP1 and RAC1 MET receptor recycling Erythropoietin activates RAS Erythropoietin activates RAS Regulation of signaling by CBL

Search Results for: CBL